ResMed Q4 Profit Rises to $383M, Revenue Up 8.6%
RMD sits 18% above its 52-week low of $180.265.
Summary
ResMed posted Q4 GAAP net income of $383.4M ($2.64/share) vs $379.7M ($2.58) a year ago, with revenue climbing 8.6% to $1.463B. Adjusted EPS came in at $2.95. The top-line growth and modest earnings beat suggest steady demand for its sleep and respiratory devices. This follows the July announcement of the MatrixCare sale to Frazier Healthcare, which may sharpen focus on the core business. No forward guidance was provided in the release.
At the time of this announcement, RMD was trading at $212.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32.4B. The 52-week trading range was $180.27 to $293.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.